

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

A novel alkaloid from the fruits of *Evodia officinalis*

Hui-Zi Jin^a; JING-LING Du^b; WEI-DONG Zhang^{ab}; HAI-SHENG Chen^b; JEONG-HYUNG Lee^c; JUNG-JOON Lee^c

^a School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China ^b Department of Natural Medicinal Chemistry, Second Military Medical University, Shanghai, China ^c Korea Research Institute of Bioscience & Biotechnology, Daejeon, Korea

To cite this Article Jin, Hui-Zi , Du, JING-LING , Zhang, WEI-DONG , Chen, HAI-SHENG , Lee, JEONG-HYUNG and Lee, JUNG-JOON(2007) 'A novel alkaloid from the fruits of *Evodia officinalis*', Journal of Asian Natural Products Research, 9: 7, 685 – 688

To link to this Article: DOI: 10.1080/10286020601103296

URL: <http://dx.doi.org/10.1080/10286020601103296>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A novel alkaloid from the fruits of *Evodia officinalis*

HUI-ZI JIN^{†*}, JING-LING DU[‡], WEI-DONG ZHANG^{†‡}, HAI-SHENG CHEN[‡],
JEONG-HYUNG LEE[¶] and JUNG-JOON LEE[¶]

[†]School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China

[‡]Department of Natural Medicinal Chemistry, Second Military Medical University, Shanghai 200433, China

[¶]Korea Research Institute of Bioscience & Biotechnology, P.O. Box 115, Yuseong, Daejeon 305-333, Korea

(Received 30 May 2006; revised 30 September 2006; in final form 12 October 2006)

Studies on the fruits of *Evodia officinalis* yielded a new quinazolinone alkaloid, wuchuyamide III (**1**), together with known alkaloids, goshuyamide II (**2**), evodiamine and rutaecarpine. Their structures were elucidated by means of 1D and 2D NMR spectroscopic analysis. Wuchuyamide III (**1**) and goshuyamide II (**2**) showed modest cytotoxicity against HeLa and HT1080 cell lines.

Keywords: *Evodia officinalis*; Wuchuyamide; Goshuyamide; Cytotoxicity

1. Introduction

The fruits of *Evodia officinalis* have long been used as a traditional Chinese drug (Chinese name “Wu-Zhu-Yu”) in the treatment of headache, abdominal pain, dysentery, postpartum haemorrhage, and amenorrhoea [1]. There were many previous studies on the *Evodia* fruit [2]. Indolopyridoquinazoline alkaloids such as evodiamine, rutaecarpine, and dehydroevodiamine, quinolone alkaloids, limonoids and flavonoids were isolated [3,4]. Further chemical studies of this plant led us to isolate one new alkaloid (**1**). Here we describe the isolation and structure elucidation of the novel alkaloid, named wuchuyamide III (**1**), and the cytotoxic effect of this compound on HeLa and HT1080 cell lines.

2. Results and discussion

Wuchuyamide III (**1**) has the molecular formula C₁₈H₁₇N₃O₃ (HRFAB-MS). The ¹H NMR and ¹³C NMR spectra indicated the presence of the three signals in the aliphatic region, including a three-proton singlet at δ 3.53 and two two-proton triplets (*J* = 7.8 Hz, each) at δ 3.24 and δ 4.26, as well as the presence of a 1,2-disubstituted benzene ring [δ 6.72 (1H, dd, *J* = 8.4, 1.2 Hz, H-3'), 7.22 (1H, ddd, *J* = 8.4, 8.1, 1.2 Hz, H-4'), 6.50 (1H, ddd, *J* = 8.4, 8.1, 1.2 Hz, H-5'), and 7.71 (1H, dd, *J* = 8.4, 1.2 Hz, H-6'); δ 116.19 (C-1'), 151.13 (C-2'), 116.96

*Corresponding author. Email: kimhz@sjtu.edu.cn




Figure 1. Structures of wuchuyamide III (1) and goshuyamide II (2).


(C-3'), 134.23 (C-4'), 114.37 (C-5'), and 131.18 (C-6')], and an 2,4-quinazolidinedione group [δ 8.03 (1H, dd, $J = 7.8, 1.5$ Hz, H-5), 7.30 (1H, ddd, $J = 7.8, 7.2, 1.5$ Hz, H-6), 7.77 (1H, ddd, $J = 8.4, 8.1, 1.5$ Hz, H-7), and 7.41 (1H, dd, $J = 8.4, 1.5$ Hz, H-8); δ 127.70 (C-5), 122.70 (C-6), 135.26 (C-7), 114.53 (C-8), 140.34 (C-9), and 114.79 (C-10)] (figure 1 and table 1). HMQC analysis allowed the assignment of all protonated carbons observed in the ^{13}C NMR spectrum. The correlation of the three-proton singlet signal at δ 3.53 to δ 30.56 indicated the presence of an N-methyl group [5]. The aromatic ring and the mutually coupled methylene signals could be located around the ketone carbonyl at δ 199.98 based on HMBC correlations between H-6' and C-7', and H-9' and C-7' [6] (figure 2). The HMBC spectrum also revealed correlations between H-9' and the two amide carbonyls δ 161.13 (C-4) and 150.18 (C-2) and between H-5 and C-4. From the above observations, **1** was deduced to be 3-[3-(2'-aminophenyl)propanone]-1-methyl-2,4-quinazolidinedione and named wuchuyamide III.

Goshuyamide II (**2**) was identified by comparison of its physical and spectral data with previous reports [7].

Table 1. ^1H NMR, ^{13}C NMR, HMBC, and $^1\text{H}-^1\text{H}$ COSY spectral data of **1**[†].

No.	δ_{C}	δ_{H}	HMBC (H \rightarrow C)	COSY
2	150.18			
4	161.13			
5	127.70	8.03 dd (7.8, 1.5)	C-4, 7, 9	6
6	122.70	7.30 ddd (7.8, 7.2, 1.5)	C-7, 8, 10	5, 7
7	135.26	7.77 ddd (8.4, 7.2, 1.5)	C-5, 9	6, 8
8	114.53	7.41 dd (8.4, 1.5)	C-6, 10	7
9	140.34			
10	114.79			
N-CH ₃	30.56	3.53 s	C-2, 9	
1'	116.19			
2'	151.13			
3'	116.96	6.72 dd (8.4, 1.2)	C-1', 5'	4'
4'	134.23	7.22 ddd (8.4, 8.1, 1.2)	C-2', 3', 6'	3', 5'
5'	114.37	6.50 ddd (8.4, 8.1, 1.2)	C-1', 3'	4', 6'
6'	131.18	7.71 dd (8.4, 1.2)	C-1', 2', 4', 7'	5'
7'	199.98			
8'	36.73	3.24 t (7.8)	C-7', 9'	9'
9'	37.68	4.26 t (7.8)	C-2, 4, 7'	8'
NH ₂		7.22 s		

[†] Recorded in CDCl₃ at 600 MHz (^1H NMR) and 150 MHz (^{13}C NMR).

Figure 2. Key HMBC correlations of **1**.Table 2. Cytotoxicities of **1** and **2**[†].

Compound	<i>IC</i> ₅₀ (μM)	
	<i>HeLa</i> cell	<i>HT1080</i> cell
1	31.32 ± 0.51	24.51 ± 1.25
2	78.83 ± 1.28	70.34 ± 1.56
Doxorubicin	0.24 ± 0.02	0.48 ± 0.01

[†]Data are mean ± SD (*IC*₅₀, μM) from two separate experiments.

Compounds **1** and **2** were examined for cytotoxicity against HeLa and HT1080 cell lines (table 2). In comparison with compound **2**, **1** showed stronger toxicity, with *IC*₅₀ values of 31.32 μM and 24.51 μM respectively in the two cell lines.

3. Experimental

3.1 General experimental procedures

Optical rotations were measured on a JASCO DIP-370 polarimeter. Melting points were measured on an Electrothermal 9100 instrument without correction. UV spectra were obtained on a UV-1601 UV-visible spectrophotometer (Shimadzu). ¹H NMR, ¹³C NMR, DEPT, and HMQC spectra were recorded on Bruker DMX 600 NMR spectrometer with CDCl₃ as a solvent. HRFAB-MS was obtained on a Platform quadrupole mass spectrometer. Preparative HPLC was carried out on J'sphere ODS-H80 (150 × 20 mm, YMC). Foetal bovine serum, media and supplement materials for cell culture were purchased from Gibco-BRL (Gaithersburg, MD, USA).

3.2 Extraction and isolation

The fruits of *Evodia officinalis* (1.8 kg) purchased from Ilsin Co. (Korea, June 2001), were extracted at room temperature with methanol. The MeOH extract (180 g) was partitioned between H₂O and EtOAc to obtain EtOAc extract (60 g). The EtOAc extract (60 g) was chromatographed on a silica gel column (5 × 60 cm) with mixtures of CH₂Cl₂/acetone (50:1, 30:1, 15:1, 10:1, 5:1, 1:1, acetone, MeOH) as eluents in a stepwise gradient mode. The fractions were combined on the basis of silica gel TLC, and 9 fractions (Fr. 1–Fr. 9) were obtained. Fraction 3 was dissolved in CHCl₃ and precipitated with MeOH. The supernatant was evaporated and subjected to silica gel chromatography eluting with

hexane/EtOAc (20:1, 10:1, 5:1, 1:1). Subfraction 3–4 was subjected to preparative TLC to give goshuyuamide II (**2**) (20 mg). Subfraction 3–5 (3 g) was eluted over silica gel column with hexane/EtOAc (5:1) to give seven fractions (3S-1–3S-7). Fraction 3S-3 was subjected to preparative HPLC (CH₃CN/H₂O, 40:60) to afford compound **1** (11 mg).

3.2.1 Wuchuyuamide III (1). Colourless prisms; $[\alpha]_D^{25} - 17$ (*c* 0.6, CHCl₃); m.p. 175.6–176.6°C; UV λ_{\max} (CHCl₃) (log ϵ) 225.6 (3.97), 242.6 (4.33), 315.2 (3.38), 325.4 (3.39), 361.0 (3.40) nm; IR ν_{\max} 3110, 1690, 1650, 1615 cm⁻¹; ¹H and ¹³C NMR, see table; HRFAB-MS *m/z* 324.1345 [M + H]⁺ (calcd for C₁₈H₁₈N₃O₃, 324.1348).

3.2.2 Goshuyuamide II (2). Colourless prisms; $[\alpha]_D^{25} + 3.7$ (*c* 0.1, CHCl₃); m.p. 138–139°C; UV λ_{\max} (CHCl₃) (log ϵ) 220.9 (4.45), 262.1 (3.78), 315.2 (3.76), 327.0 (3.68) nm; ESI-MS *m/z* 320.13 [M + H]⁺.

3.3 Cytotoxicity assay

A cytotoxicity assay was carried out according to Denizot and Lang [8]. Each cell (concentration of 1 × 10⁴) was seeded in each well containing 100 μ l DMEM. Subsequently, various concentrations of samples were added. The cells were incubated for 48 h at 37°C in an atmosphere containing 5% CO₂, then 10 μ l FBS-free medium containing 5 mg/ml MTT was added to the wells. After 4 h of incubation at 37°C, the medium was discarded and the formazan blue formed in the cells was dissolved by adding 100 μ l DMSO. Optical density was measured at 570 nm using a microplate reader (Molecular Devices Co., Menlo Park, CA, USA). Doxorubicin was used as a positive control.

Acknowledgements

This work was supported in part by a grant from Korea Research Institute of Bioscience and Biotechnology Research Initiative Program and a research grant (PF0320701-00) from Plant Diversity Research Centre of 21st Frontier Research Program funded by the Korean Ministry of Science and Technology.

References

- [1] *Encyclopedia of Chinese Medicine*, p. 1118, People's Press, Shanghai, China (1977).
- [2] W. Tang, G. Eisenbrand. *Chinese Drugs of Plant Origin*. pp. 509–519, Springer, Berlin (1992).
- [3] Y.Q. Tang, X.Z. Feng, L. Huang. *J. Chin. Pharm. Sci.*, **6**, 65 (1997).
- [4] T. Sugimoto, T. Miyase, M. Kuroyanagi, A. Ueno. *Chem. Pharm. Bull.*, **36**, 4453 (1988).
- [5] D.L. Dreyer, R.C. Brenner. *Phytochemistry*, **19**, 935 (1980).
- [6] B.H. Moon, Y.C. Park, J.B. McClintock, B.J. Baker. *Tetrahedron*, **56**, 9057 (2000).
- [7] N. Shoji, A. Umeyama, A. Iuchi, N. Saito, S. Arihara. *J. Nat. Prod.*, **52**, 1160 (1989).
- [8] F. Denizot, R. Lang. *J. Immunol. Methods*, **89**, 271 (1986).